# US 2024/0208903 A1 · Acid addition salts of (s)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (s)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl)phenyl)piperidine, specific polymorphs thereof and methods for their manufacture

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0208903 A1
- Document ID: US20240208903A1
- Status: Published application
- Kind: A1
- Application number: 18/556,295
- Filed: 2022-05-05
- Published: 2024-06-27
- Earliest claimed: 2021-05-06
- Assignees: Lophora ApS
- Applicants: Lophora Aps
- Inventors: Jesper Langgaard KRISTENSEN; Emil MÄRCHER-RØRSTED
- Web page: https://patentgrep.com/patent/US20240208903A1

## CPC

- C07D 211/02: Preparation by ring-closure or hydrogenation
- C07D 211/20: with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D 211/12: with only hydrogen atoms attached to the ring nitrogen atom
- C07D 211/22: by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to certain pharmaceutically acceptable salts of (S)-3-(2,5-dimethoxy-4-(trifluoromethyl)phenyl)piperidine and (S)-3-(2-methoxy-5-(methylthio)-4-(trifluoromethyl) phenyl)piperidine and specific polymorphs thereof. More particularly, the present invention relates to the compounds of Formula (VI) as well as chemical routes for their manufacture.

## Claims

### Claim at position 1

1-19. (canceled)

### Claim 20

A method for the manufacture of a compound of Formula (VI) comprising the steps of:
a) reacting the compound of Formula (III), wherein PG is an amine protecting group,
in a solvent with hydrogen gas (H2) in the presence of a transition metal catalyst to obtain a racemic compound of Formula (IVa) or (IVb)
or, alternatively, reacting the compound of Formula (III) in a solvent, with a deprotection reagent to obtain a compound of Formula (IIIa)
b) reacting the compound of Formula (IVa), if formed in step a), in a solvent with a deprotection reagent to obtain a racemic compound of Formula (IVb),
or, alternatively, reacting the compound of Formula (IIIa) if formed in step a), in a solvent, with hydrogen gas (H2) in the presence of a transition metal catalyst to obtain a racemic compound of Formula (IVb)
c) reacting a compound of Formula (IVb) with a chiral acid in a solvent to obtain a compound of Formula (V) having an enantiomeric excess (ee) of at least 70%,
wherein X− is the conjugate base of the chiral acid,
and liberating the salt of Formula (V) to obtain the compound of Formula (S)-(IVb)
d) reacting the compound of Formula (S)-(IVb) in a solvent with succinic acid, L-tartaric acid, or HCl to obtain a crystalline compound of Formula (VI),
wherein
Y is selected from S or O,
A− is selected as 3-carboxypropanoate, (2R,3R)-3-carboxy-2,3-dihydroxypropanoate or chloride (Cl−).

### Claim 21 (depends on 20)

A method according to claim 20, wherein the chiral acid in step c) is selected from (−)—O,O′-Di-p-toluoyl-L-tartaric acid or (−)-Di-p-anisoyl-L-tartaric acid, preferably (−)-Di-p-anisoyl-L-tartaric acid.

### Claim 22

A method for the manufacture of a compound of Formula (VI), comprising the steps of:
a) reacting the compound of Formula (III), wherein PG is an amine protecting group,
in a solvent with hydrogen gas (H2) in the presence of a transition metal catalyst, and a chiral ligand, to obtain a compound of Formula (S)-(IVa) or (S)-(IVb), having an enantiomeric excess (% ee) of at least 70%,
or reacting the compound of Formula (III) in a solvent, with a deprotection reagent to obtain a compound of Formula (IIIa)
b) reacting the compound of Formula (S)-(IVa), if formed in step a), in a solvent with a deprotection reagent to obtain a compound of Formula (S)-(IVb) having an enantiomeric excess (% ee) of at least 70%,
or alternatively, reacting the compound of Formula (IIIa), if formed in step a), in a solvent with hydrogen gas (H2) in the presence of a transition metal catalyst and a chiral ligand, to obtain a compound of Formula (S)-(IVb), having an enantiomeric excess (% ee) of at least 70%,
c) reacting the compound of Formula (S)-(IVb) in a solvent with succinic acid, L-tartaric acid, or HCl to obtain a crystalline compound of Formula (VI),
wherein A− is selected as 3-carboxypropanoate, (2R,3R)-3-carboxy-2,3-dihydroxypropanoate or chloride (Cl−).

### Claim 23 (depends on 22)

A method according to claim 22, wherein the chiral ligand is (R,R)-i-Pr-DuPhos.

### Claim 24 (depends on 20)

A method according to claim 20, wherein the method further comprises a step a1), prior to step a), of:
a1) reacting a compound of Formula (I) with a compound of Formula (II) in a solvent,
wherein Z is selected from the group consisting of a boronic acid, a trifluoroborate salt and boronic esters,
PG is an amine protecting group,
Y is selected from S or O,
X is selected from Cl, Br, I or OTf,
in the presence of a base and a transition metal catalyst to obtain a compound of Formula (III)

### Claim 25 (depends on 20)

A method according to claim 20, wherein PG is a carbamate protecting group, an amide protecting group, a benzylamine protecting group, a triphenylmethylamine protecting group, or a sulfonamide protecting group, preferably a carbamate protecting group, most preferably tert-Butyloxycarbonyl group (Boc).

### Claim 26 (depends on 20)

A method according to claim 20, wherein the deprotection reagent is an acid, preferably HCl.

### Claim 27

A crystalline compound of Formula (VI),
wherein
A− is 3-carboxypropanoate and the salt is the polymorph with the XRPD spectrum having 2θ peaks 4.0770, 8.1080, 11.9910, 12.1560, 13.8930, 15.8760, 16.2180, 16.412, 16.5960, 17.8490, 19.5070, 19.786°, 20.031°, 20.297°, 21.122°, 22.011°, 22.635°, 23.000°, 23.268°, 24.065°, 24.408°, 25.414°, 25.758°, 26.947°, 27.751°, 28.032°, 28.314°, 29.966°, 30.358°, 30.562°, 30.770°, 31.378°, 32.306°, 32.868°, 33.505°, 34.710°, 35.206°, 36.418°, 36.714°, 37.306°, 38.147°, 38.322°, 38.745° as shown in FIG. 1, or
A− is (2R,3R)-3-carboxy-2,3-dihydroxypropanoate and the salt is the polymorph with the XRPD spectrum having 20 peaks 5.925°, 10.183°, 11.313°, 11.823°, 12.209°, 12.542°, 15.233°, 15.592°, 15.776°, 16.275°, 16.719°, 17.063°, 17.406°, 17.752°, 18.012°, 19.568°, 19.692°, 20.291°, 20.746°, 21.261°, 21.839°, 22.200°, 22.700°, 23.226°, 23.372°, 23.603°, 23.962°, 24.516°, 24.707°, 25.013°, 25.440°, 25.914°, 26.502°, 27.003°, 27.496°, 27.902°, 28.365°, 28.786°, 29.078°, 29.791°, 30.027°, 30.299°, 30.785°, 31.187°, 31.686°, 32.070°, 32.392°, 33.434°, 33.862°, 34.358°, 34.790°, 35.584°, 36.277°, 36.801°, 37.197°, 38.121° and 39.667° as shown in FIG. 3., or
A− is selected as chloride (Cl−) and the salt is the polymorph with the XRPD spectrum having 20 peaks 7.457°, 9.185°, 10.899°, 11.738°, 12.604°, 14.956°, 17.706°, 18.215°, 18.382°, 19.307°, 19.902°, 20.442°, 20.956°, 21.850°, 22.449°, 23.781°, 24.007°, 24.357°, 24.752°, 25.327°, 25.557°. 26.064°, 27.377°, 27.702°, 28.340°, 28.557°, 29.144°, 29.366°, 29.915°, 30.164°, 30.669°, 30.975°, 32.213°, 32.725°, 33.018°, 33.742°, 34.605°, 35.012°, 35.618°, 36.883°, 37.131°, 37.250°, 37.772°, 38.358°, 38.626°, 39.140°, 39.869° as shown in FIG. 2.

### Claim 28 (depends on 27)

A crystalline compound according to claim 27, wherein A− is 3-carboxypropanoate and the salt is the polymorph with the XRPD spectrum having 20 peaks 4.077°, 8.108°, 11.991°, 12.156°, 13.893°, 15.876°, 16.218°, 16.412, 16.596°, 17.849°, 19.507°, 19.786°, 20.031°, 20.297°, 21.122°, 22.011°, 22.635°, 23.000°, 23.268°, 24.065°, 24.408°, 25.414°, 25.758°, 26.947°, 27.751°, 28.032°, 28.314°, 29.966°, 30.358°, 30.562°, 30.770°, 31.378°, 32.306°, 32.868°, 33.505°, 34.710°, 35.206°, 36.418°, 36.714°, 37.306°, 38.147°, 38.322°, 38.7450 as shown in FIG. 1.

### Claim 29 (depends on 27)

A crystalline compound according to claim 27, wherein the crystalline compound has crystals with a particle size ranging from ˜5 to ˜50 m.

### Claim 30

An intermediate compound of Formula (III) or (IIIa),
wherein Y is selected from O or S,
PG is a carbamate protecting group, an amide protecting group, a benzylamine protecting group, a triphenylmethylamine protecting group, or a sulphonamide protecting group.

### Claim 31 (depends on 30)

The intermediate compound according to claim 30, wherein the amine protecting group is a carbamate protecting group, an amide protecting group, a benzylamine protecting group, a triphenylmethylamine protecting group, or a sulphonamide protecting group, preferably a carbamate protecting group.

### Claim 32 (depends on 30)

An intermediate compound according to claim 30, wherein a carbamate protecting group is selected from 9-Fluorenylmethyl carbamate (Fmoc-NR2), t-Butyl carbamate (Boc-NR2), or Benzyl carbamate (Cbz-NR2); an amide protecting group is selected from acetamide (Ac-NR2) or Trifluoroacetamide (CF3CO—NR2); a benzylamine protecting group is selected from Benzylamine (Bn-NR2) or 4-methoxybenzylamine (PMB-NR2); a triphenylmethylamine protecting group is triphenylmethylamine (Tr-NR2); a sulphonamide protecting group is p-Toluenesulfonamide (Ts-NR2).

### Claim 33 (depends on 30)

An intermediate compound according to claim 30, wherein Y is O.
